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1. Introduction 
In ulcers’ healing the organic contaminations causes a problem that are not scrupulously 
removed by patients or medical personnel, particularly, where approximately 90 % patients 
suffering from the disease have been cured in an open system care. Secondly, up to the latest 
days there was no appropriate medicine effectively supporting wound’s cleaning. Necrotic 
organic substances remaining in the wound do activate a holder’s immunological system 
and promote bacteria, fungi, and virus increments, in which environment reactive oxygen 
species are created. These very aggressive substances destroy healthy tissues and favour 
accumulating significantly extensive amount of granulocytes which, in turn, affect micro-
obstructions and micro-clots in the wound’s edge area. The mentioned circumstances 
suspend the healing or even preclude this process. Another issue is, that majority of patients 
do not rinse up the whole wound surface while the edges only or they do not change 
bandages sufficiently often. A commonly used salt to rinse the wound is a physiological salt 
or Ringer’s liquid. However, these are the liquids which do not contain a conservation 
mean. Therefore, outstaying usually in an open way for many days, or more often in a room 
temperature, the solutions can be secondarily contaminated. What is more, patients often 
use a tap water which is also bacterially contaminated. Having in mind a nature of the 
wound’s protein components, which are strongly associated with a substratum via fibrins, it 
is not indifferent what the wound is rinse up with (1,2,3,4).  
In the study, the Authors present a new tactics against lasting wounds. It relies on 
supplementing the TIME procedure by the Lav acronym which means lavage (washing, 
cleaning) in the first instance, before wound treatment. Moreover, an effectiveness of wound 
cleaning from the organic elements including bacteria using a physiological salt (NaCl) and 
Prontosan (polyhexanide+betaine) has been reported (5,6).  
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2. Material and method 
In the study have been enrolled 60 patients (19 males and 41 females, 47-83 of age with 58.5 
average). Retired persons (52 patients) were predominant in the group, widowers (43), alone 
(39) and inhabitants of a >100 thou. population city (38). All the patients have been suffering 
from thrombosis for 2-15 years. In the color duplex Doppler’s test in all the patients signs of 
post thrombotic syndrome with damage of venous valves on different levels of the 
extremity has been diagnosed. A valve damage in femoral vein was predominant in 49 
patients (formerly treated but unsuccessfully).  
 Male  Female Total  
Gender  19 41 60 
Retired  14 38 52 
Widower 9 34 43 
Alone 7 32 39 
Citizen of > 100 thou. 
population city 
12 26 38 
Kind of profession 
a/ physical worker, 
farmer 
b/ office worker 
c/ student 
 
11 
 
6 
2 
 
27 
 
14 
0 
 
38 
 
20 
2 
Age 56 +/- 14 63 +/- 14  
Median 55 62  
Range (20-87) (24-88)  
BMI 27,3 +/- 5,3 28,7 +/- 5,1  
Median 25 27  
Range (16,2-38,2) (15,7-39,1)  
Table 1. The patient demographics 
In the study 30 patients were taken into account with 44 ulcers’ histories (158 visit records). 
From the preliminary set of 60 patients, those were excluded who appeared once or who did 
not restrict the regimes of the treatment procedure. After decoding the bottles’ containments 
and appropriate patients’ assigning to the groups, it was established that 17 patients were 
treated by Prontosan, whereas 13 by the 0.9% NaCl solution, respectively.  
Drop out patients are presented in table 2. 
 Prontosan group 0.9% NaCl group Total  
Adverse events 3 2 5 
Major protocol violation 2 4 6 
Patient wished to leave study 3 5 8 
Patient not compliant 4 3 7 
Significant concomitant illness 1 3 4 
Treatment failure 0 0 0 
Total 13 17 30 
Table 2.  
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2.1 Study design 
This study was an open, multicenter, prospective, randomized, double blind, parallel group 
study on efficacy of Prontosan solution in treatment of venous leg ulcers. 
The study was performed in 3 centers and was included a total number of 60 patients. After 
dropped out 30 patients because of different reasons remaining patients were as follow : 17 
patients for Prontosan and 13 for 0.9% NaCl subgroup. Treated venous leg ulcers were 
classified according to ABI /Ankle-Brachial Index/. The venous leg ulcers were recognized 
when ABI was higher than or equal to 0,9 and no lymphatic disorders revealed. 
All study participants had been treated during 12 weeks or until complete healing is 
achieved (whichever occurs first). 
2.2 Study population 
The study population consists of individuals above 18 years of age, in which venous leg ulcers 
have been identified of the size limited by the size of applied wound dressing and ABI ≥ 0.9.  
Exclusion criteria were as follows: 
a. hypersensitivity to any of Prontosan® components or to any of wound dressing 
components,  
b. active osteomyelitis in the area of the treated ulcer,  
c. active rheumatoidal or collagen disease of blood vessels treated with corticosteroids, 
d. neoplastic disease 
e. serum proteins < 4 g/dl 
f. anemia: < 10g haemoglobin per dl 
g. exclusion of phlebotropic, vasorelaxing and reological medicines for the study period  
h. diabetic foot 
i. lack of compliance of the patient 
j. intolerance to compression therapy 
2.3 Route of administration 
External application. 
2.4 Dosage regimen 
Either Prontosan® or saline solution (depending on the study group) had been applied at 
every change of the wound dressing. Frequency of dressing change: every day. 
3. Application 
1. first, Prontosan/saline solution was used for cleansing of the wound bed; this will be 
done using sterile gauze & sterile gauze compress soaked in the solution an used to 
cover the wound for 15 min, then removed from the wound bed 
2. next, the polyurethane wound dressing was activated with given solution and used to 
cover the wound 
3. finally, medical compression stockings was used to fasten the wound dressing to the 
patient’s leg. 
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Prontosan or 0.9% NaCl solution were used to soak and gently remove the wound dressing 
at the time of each dressing change procedure.  
For each patient 10 bottles 350 ml of Prontosan or 0.9% NaCl saline solution were available 
and used as necessary according to applied randomization scheme.  
3.1 Efficacy criteria 
Primary efficacy criteria:  
1. incidence of infection during treatment period 
2. rate of healing of the ulcer in cm2/week 
Secondary efficacy criteria: 
1. complete healing of the ulcer – ulcer is defined as completely healed if there is stable 
wound epithelialization 
2. improved state of the ulcer – ulcer is defined as improved if there is decrease in its 
surface of at least 25% in comparison to the initial findings 
3. lack of improvement of the ulcer – defined as the ulcer that do not belong to any of the 
above listed categories 
Tertiary efficacy criteria: 
1. incidence of pain during dressing change, comfort for the patient – subjective pain scale 
used during the course of study - before, during and after each dressing change (CIVIQ 
questionnaire) 
2. incidence of side effects 
3. change of clinical symptoms of the ulcer (granulation, epithelialization; computer-aided 
analysis of digital pictures of the wound). 
3.2 Methods of evaluation of the efficacy of treatment include: 
- planimetry of the ulcer, software-aided surface evaluation,  
- assessment of clinical status of the ulcer (computer-aided analysis of pictures of wound 
surface) 
- assessment of changes in microbial load in the ulcer in first, second & last visit of the 
study  
- photographic documentation of the treatment (done in a standardized way to allow for 
further computer-aided analysis) 
- laboratory tests: full blood count, total proteins 
3.3 Safety evaluation  
Assessment of differences between measured general health parameters (as listed under 
laboratory tests) as well as incidence of adverse reactions before and after therapeutical 
process. 
Following the study qualification during the initial visit (D-0), for bacteria culture 
inoculation, swabs from the wounds were taken and bottles with unknown liquid together 
with the treatment prescription among the patients were distributed. During the control 
visits before bandaging a digital photographical documentation of healing was conducted.  
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The treatment procedure consisted with: 
Every day applying wet gauze with the liquid from the bottle. The dressing was on the 
wound during fifteen minutes than polyurethan wound dressing ( Allevyn ) was put on. 
Such dressing was covered by two knee stockings. First was a thrombo profilactic and the 
second one was Sigvaris 503 class compression. Day by day patient change the dressings 
according to above mentioned method. To make easier for the patients each one get diary 
with detail prescription how to use getting materials for the treatment.  
The visits’ D-13 and D-31, D-58 consisted with: check the wound healing process, make a 
digital photography, take the culture from the wound bed, put the new dressing on, take 
used bottles off and give new bottles with the medicament. 
The last visit was D-85. During this visit physician estimated the healing process, advers 
events and ask patients about their satisfaction with the treatment. 
4. Statistical analysis 
In the statistical analysis, hierarchical (multi-level) modelling has been performed that 
allows variance in outcome variable (wound surface) to be analysed at multiple hierarchical 
levels (i.e. time of treatment, treatment groups and their interaction) [Raudenbush S., Bryk 
A. (2001). Hierarchical Linear Models: Applications and Data Analysis Methods (2nd ed.). 
Sage Publications, Thousand Oaks CA]. A mixed effects’ model has been applied in the 
study.  
A statistical difference between means of the speed of ulcers’ healing in Prontosan and NaCl 
patients has been estimated with the use of Welch’s t-test that is an adaptation of Student’s 
t-test intended for use with two samples having possibly unequal variance [Welch B. (1947). 
The generalization of “student's” problem when several different population variances are 
involved. Biometrika 34: 28-35] for details.  
A so-called k-means algorithm which classifies a given data set (speed of ulcers’ healing) 
through a certain number of clusters (two time bands) [MacQueen J. (1967). Some Methods 
for classification and Analysis of Multivariate Observations. Proceedings of 5-th Berkeley 
Symposium on Mathematical Statistics and Probability. Berkeley, University of California 
Press 1:281-297].  
A statistical difference in infection numbers between the selected Prontosan and NaCl 
patients’ visits has been estimated through the Mann-Whitney U-test [Mann H., Whitney D. 
(1947). On a test of whether one of two random variables is stochastically larger than the 
other. Annals of Mathematical Statistics 18: 50-60], which is a non-parametric test and 
assesses whether two independent samples of observations (infection numbers in treatment 
groups) come from the same distribution.  
The statistical computation has been conducted in R platform [The R Foundation for 
Statistical Computing (2008). R version 2.8.1 (2008-12-22)].  
The planimetrical estimation of ulcers was carried out based on digital pictures of wounds 
with the use of the MapInfo 6.5 geographical software.  
www.intechopen.com
 
Pharmacotherapy 
 
186 
5. Results 
In the group of patients underwent study were 11 smokers but only two smokers belongs to 
the group of assessed patients, one in group of Prontosan and one in 0.9% NaCl group. 
The ulcer location was predominantly in ankle region (49 ), above ankle ( 11). Status of the 
wound before and following treatment are presented in table 3. 
Status of the wound Before 
treatment 
Prontosan 
Before 
treatment 
0.9% NaCl 
After treatment 
Prontosan 
After treatment 
0.9% NaCl 
necrosis 7 6 0 1 
Fibrinogen coating 17 13 0 2 
Infection  9 6 2 5 
Visible tendoms 5 3 2 2 
Fistulas 0 0 0 0 
Granulation faze   17 9 
Epithelialization faze 0 0 17 3 
Table 3. 
Total healing rate in the estimated groups is presented in table 4 
 Prontosan n = 17 0.9% NaCl n = 13 
Total healing of ulcer within 
90 days 
16 6 
85% of ulcer healing 1 3 
50% of ulcer healing 0 3 
30% of ulcer healing 0 1 
Lack of improvement of the 
ulcer  
0 0 
Table 4. 
All blood and urine tests were in of normal range before and following study procedure. 
Only in three patients of Prontosan group appeared adverse events listed in table 5. 
 Prontosan n = 17 0.9% NaCl n = 13 
Serious adverse events 0 0 
Not serious adverse events   
Headache  0 1 
Excitation/sleepless 0 0 
Stabbing pain of the heart 0 0 
Nausea  0 0 
Itching  2 3 
Eruption of the skin 1 3 
Oedema foots and legs 0 2 
Table 5. 
www.intechopen.com
LavTIME –a Brand-New Treatment Method of Lasting Wounds –  
A Multi-Centre Randomized Double-Blind Study on Effectiveness of Polyhexanide...  
 
187 
In the study 30 patients (17 Prontosan and 13 0.9% NaCl) were taken into account with 44 
ulceration episodes (mean age = 71.9 +/- 10.7). All together in 2008 and 2009, 158 visits were 
documented in the form below:  
Episode  Treatment  Time since 1st visit [days]  Time between visits [days]  Surface [mm^2]  
1  Prontosan  0  0  3006,7  
1  Prontosan  42  42  2057  
1  Prontosan  75  33  1240,9  
1  Prontosan  151  76  183,6  
1  Prontosan  186  35  33,4  
1  Prontosan  224  38  64,2  
2  NaCl  0  0  110,6  
2  NaCl  14  14  178,6  
2  NaCl  17  3  176  
2  NaCl  57  40  45,9  
2  NaCl  71  14  30,1  
3  NaCl  0  0  286,2  
3  NaCl  17  17  198,5  
3  NaCl  33  16  133,3  
4  NaCl  0  0  476,2  
4  NaCl  14  14  510  
4  NaCl  70  56  467  
4  NaCl  91  21  419,8  
*****  *******  *****************  *****************  **********  
 
Fig. 1. 
The average ulcer surface area vs 
time of all treated patients 
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Fig. 2. 
The regression estimates of the assumed hierarchical model are reported in Table 6. 
Parameter  Value  Std. Error  p-value  
intercept  1012,796  178,385  <0,0001  
time  -4,053  1,168  0,0007  
groupProntosan  -86,154  194,633  0,6589  
time:groupProntosan  -5,004  1,479  0,0010  
Table 6. Hierarchical Modelling Analysis 
 A statistically significant reduction of the surface of ulcers in Prontosan and in NaCl 
patiens was observed approximately 4 mm2 per day (time); 
Prontosan patients represented a larger reduction of the wound surface during 
treatment compared to NaCl patients (86 mm2 in average) , however, the difference was 
not statistically significant (groupProntosan); 
 A statistically significant difference in healing effect in time between the treatment 
groups was observed and for each therapy increment of one day, the reduction of 5 
mm2 was larger approximately in Prontosan patients compared to NaCl group 
(time:groupProntosan). 
The graphical model of the reduction of ulcers in treatment groups is presented in Figure 3.  
The average ulcer surface area vs 
time between treatment and control 
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Fig. 3. 
The regression model estimates indicate that a particular 1000 mm2 ulcer wound should be 
approximately healed after 110.4 days of Prontosan therapy whereas 246.8 days with the 
NaCl treatment.  
The estimates of the statistical difference between means of the speed of ulcers’ healing in 
Prontosan and in NaCl patients are presented below 
Treatment Mean Std. Dev. p-value 
Prontosan 13,320 14,763 0,01465 
NaCl 5,641 18,124  
Table 7. Ulcers’ Healing Speed t-test (mm2) 
The t-test estimates provide evidence of the over twice as high ulcer reduction in Prontosan 
treatment patients compared to NaCl group. The average healing in Prontosan patients 
exceeded 13 mm2 per day whereas in NaCl patients it was much below 6 mm2 daily. The 
difference in means is statistically significant.  
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Fig. 4. Time-Speed Clusters of Ulcers' Healing in: Prontosan Patients 
 
Fig. 5. Time-Speed Clusters of Ulcers' Healing in: NaCl patients 
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Treatment  Means   
 Cluster 1  Cluster 2  p-value  
Prontosan  14,770  5,164  0,00931  
NaCl  5,730  5,347  0,9152  
Table 8. The t-test analysis for the time-speed clusters in Prontosan and NaCl patients are 
given 
The outcomes testify that there is a significant difference in means of healing speed in 
Prontosan patients between the estimated clusters. The obtained time band can be 
established around the 100 days since the beginning of Prontosan treatment and the average 
speed of ulcer healing reaches nearly 15 mm2 per day up to this time border. After this time 
the speed decreases significantly to 5 mm2/day. The healing speed in NaCl patients does 
not vary with time and in both clusters it is slightly above 5 mm2 per day of treatment. 
Treatment No. of Obs. Rank Sum U statistic Z statistic p-level 
Prontosan 27 509,5 131,5 -3,9054 9,43E-05 
NaCl 26 921,5    
Table 9. The U-test results for the infection numbers between the selected Prontosan and 
NaCl patients’ visits are reported U-Test Infection Numbers Analysis 
The results provide evidence of significantly lower infection numbers in Prontosan patients’ 
ulcers in comparison to the NaCl group (nearly twice as low).  
6. Discussion 
In the study 30 patients were taken into account with 44 ulcers’ histories (158 visit records). 
From the preliminary set of 60 patients, those were excluded who appeared once or who did 
not restrict the regimes of the treatment procedure. After decoding the bottles’ containments 
and appropriate patients’ assigning to the groups, it was established that 17 patients were 
treated by Prontosan, whereas 13 by the NaCl solution, respectively.  
The obtained outcomes provide evidence nearly three times as a higher healing speed in 
those patients who were treated by Prontosan in comparison to the NaCl group. The 
cleaning from bacteria tribes was as twice as higher, respectively. In both the analyses the 
results were statistically significant.  
The importance of lavasepsis for the treatment of chronic wounds results from a 
fundamental, commonly understood and accepted standard, which for wound management 
field translates as follows: “first wound hygiene, then wound tratment (7).” This principle 
goes hand in hand with the generally accepted rule of limiting the use of drugs to an 
essential minimum and giving prophylaxis priority in medicine. What is then the real 
impact of lavasepsis on the individual elements of the TIME framework? 
The effect of lavasepsis on Tissue management is many-sided. It softens and separates 
necroses from healthy tissue, which facilitates their identification and elimination. 
Furthermore, lavasepsis removes crust, scabs and exudate residues, as well as fibrin 
coatings from the wound surface (8, 9). Finally, everyday wound lavasepsis secures effective 
biofilm removal (10). Wound lavasepsis cannot replace surgical interventions or sharp 
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debridement, but it can considerably help in assessment of the wound and in effective 
employment of the required procedure.  
In the area of Inflammation and infection control, it is worth emphasising the significance of the 
aforementioned cleansing properties, namely the removal of wound coatings and biofilm 
from the wound surface. The use of antiseptics and antibiotics for a wound that is either 
contaminated or coated with a biofilm is inadequate. It can cause the therapy to be 
ineffective and increases the likelihood of the development of drug-resistance (12, 14). 
Wound cleansing or hygiene lowers the microbial load and significantly lowers the risk of 
complications, including infections. The microcirculation, oxygen and nutrient availability, 
as well as the effectiveness of patient’s immune system are improving. Lavasepsis cannot 
replace antisepsis, but secures optimal conditions for the use of local and systemic anti-
infectives. In this way, it minimizes and streamlines their application.  
Maintaining an adequate Moisture balance of the wound is an important element of the 
therapeutic process. Everyday wound lavasepsis helps to remove excessive exudate (also by 
reinforcing the habit of wound cleansing). It facilitates wound moistening in the case of dry 
wounds and raises the effectiveness of wound dressings. Lavasepsis is not meant to replace 
modern wound dressings, which are essential for maintaining a moist wound environment 
and absorbing excessive exudate. It can, however, prepare the wound bed in a way that 
ensures optimal therapeutic effect of their application. 
Epithelial/edge advancement is an element of the TIME framework, for which lavasepsis is 
important because of the fact that the removal of wound coatings facilitates the 
reestablishment of cellular proliferation and angiogenesis. Lavasepsis also removes 
potential physical barriers to epithelial growth across the wound bed. Finally, optimal 
wound bed preparation is a prerequisite for effective use of advanced therapies, such as skin 
transplants and cellular growth factors (11).  
Lavasepsis thus has a significant influence on all elements of the TIME framework, being a 
process of preparing the wound bed per se. Thanks to this, it allows one to achieve optimal 
results from any therapeutic procedures applied at specific stages of wound treatment. 
The above outcomes point to the conclusion that a lack of effective wound cleaning from 
organic elements laying on the wound bed as well as from the remained bacteria (protected by 
the bacterial biofilm which is difficult to remove using physiological salts) result in significant 
elongation of the healing time. Prontosan dissolves and removes contaminations from the 
wound bed, destroys the bacterial biofilm and accelerates the healing of ulcers. Despite of a 
slightly higher price, the use of Prontosan may importantly reduce sufferance in patients 
likewise both the costs carried out by their own and the governmental subsidies, taking the 
time of the medical treatment in mind. Further economical simulation are required to estimate 
such the profits. Our results were confirmed by other investigators (12). 
Lavasepsis is a new term created to describe and delineate a group of products that, 
according to the authors, brings in a new, desired quality to local treatment of chronic 
wounds (13). This new quality arises directly from the evolution of the WBP paradigm and 
TIME framework set earlier by EWMA experts (14). The TIME framework and EWMA 
recommendations are a good milestone not only for clinical practice, but also for 
manufacturers who are trying to adopt their product offering to the needs of contemporary 
medicine. The LAV-TIME concept presented in this paper, extends and supplements the 
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TIME framework with the new and important element of lavasepsis (15,16,17,18). Although 
at present there are few products on the market that can be described as “lavaseptics”, the 
rapid development of this group of products is to be expected, and their availability on the 
medical market will grow. This would certainly be of benefit to the medical world, and most 
of all to the patients (19,20). 
7. Conclusion 
1. A statistically significant difference in healing effect in time between the treatment 
groups was observed and for each therapy increment of one day, the reduction of 5 
mm2 was larger approximately in Prontosan patients compared to NaCl group. 
2. The results provide evidence of significantly lower infection numbers in Prontosan 
patients’ ulcers in comparison to the NaCl group. 
3. Prontosan appeared as a very good tolerated product for patients without any serious 
adverse effects. Only three out of seventeen patients have a temporary local problems 
with Itching ( two patients ) and eruption of the skin ( one patient ). 
4. 16 patients out of 17 in the Prontosan group were totally healed within 90 days of 
treatment and only 6 out of 13 were totally healed in NaCl group at the same time. 
8. References 
[1] Kramer A, „Antiseptika und Haࡇndedesinfektionsmittel“. W: Korting HC, Sterry W 
(Hrsg) Therapeutische Verfahren in der Dermatologie. 2001, Blackwell 
Wissenschaft Berlin, 273-294. 
[2] Kramer A, Adrian V, Rudolph P, Wurster S, Lippert H, “Explantationstest mit Haut und 
Peritoneum der neonatalen Ratte als Voraussagetest zur Vertra ࡇglichkeit lokaler 
Antiinfektiva fuࡇr Wunden und Koࡇrperho ࡇhlen“. 1988, Chirurg 69, 8:840-845. 
[3] Kallenberger A, Kallenberger C, Willenegger H, „Experimentelle Untersuchungen zur 
Gewebevertra ࡇglichkeit von Antiseptika“. 1991, Hyg Med 16, 10:383-395. 
[4] Sellmer W, „Lokaltherapeutika, speziell Antiseptika, in der Behandlung chronischer 
Wunden – eine aktuelle Bewertung“. 2001, Med Praxis 2: 20-30. 
[5] Schmit-Neuerburg KP, Bettag Ch, Schlickewei W, Fabry W, Hanke J, Renzing-Koࡇhler K, 
Hirche H, Kock H-J, „Wirksamkeit eines neuartigen Antisepticum in der 
Behandlung kontaminierter Weichteilwunden“. 2001, Chirurg 72: 61-71. 
[6] Seipp H-M et al., „Wirksamkeit verschiedener Wundspuࡇlloࡇsungen gegenu ࡇber 
Biofilmen“. 2005, Zeitschrift fuࡇr Wundheilung, 1, 160-164. 
[7] European Wound Management Association (EWMA). Position Document: Wound Bed 
[8] Preparation in Practice. London: MEP Ltd. 2004 
Ciesielczyk P, Rybak Z, „Prawidłowe przygotowanie łozࡆyska rany i profilaktyka  
[9] antybakteryjna – droga do sukcesu w leczeniu ran. Zastosowanie Prontosanu i 
produktów PVP-jodowych”. Streszczenia. II Kongres Naukowo-Szkoleniowy 
Polskiego Towarzystwa Leczenia Ran. 2007, Leczenie Ran 4(4): 140. 
[10] Kramer A et al., “Consensus recommendation on wound antisepsis”. 2004, Zeitschrift 
fuࡇr Wundheilung 3. 
[11] Werner HP, „Die mikrobizide Wirksamkeit ausgewaࡇhlter Antiseptika“. 1992, Hyg Med 
17, 2:51-59.   
www.intechopen.com
 
Pharmacotherapy 
 
194 
[12] Kramer A, Adrian V, Rudolph P, Wurster S, Lippert H, “Explantationstest mit Haut 
und Peritoneum der neonatalen Ratte als Voraussagetest zur Vertra ࡇglichkeit lokaler 
Antiinfektiva fuࡇr Wunden und Koࡇrperho ࡇhlen“. 1988, Chirurg 69, 8:840-845. 
[13] Kallenberger A, Kallenberger C, Willenegger H, „Experimentelle Untersuchungen zur 
Gewebevertra ࡇglichkeit von Antiseptika“. 1991, Hyg Med 16, 10:383-395. 
[14] Sellmer W, „Lokaltherapeutika, speziell Antiseptika, in der Behandlung chronischer 
Wunden – eine aktuelle Bewertung“. 2001, Med Praxis 2: 20-30. 
[15] Selvaggi G et al., „The role of iodine in antisepsis and wound management: a 
reappraisal”. 2003, Acta chir. belg 103, 241-247. 
[16] Seipp H-M and Stroh A, “Methicillin-resistant S. aureus (MRSA) – Significant reduction 
of incidence and rate in a maximum-care clinical centre (1994 to 1999)”. 1999, Hyg 
Med 24 (6): 224-237. 
[17] Ciesielczyk P., Michalski T., Rybak Z.: LA V-TIME. Ewolucja paradygmatu,2007, 
Zakaz ࡆenia;6:104-108. 
[18] Rybak Z.: Venous leg ulcers, 2008, Sepsis;1(2):95-98. 
[19] Rybak Z., Cisielczyk P.: Lavasepsis as a helpful method in wound treatment, 2008, 
Dermat. Estet;10(2):104-106. 
[20] Kramer A, „Antiseptika und Handedesinfektionsmittel“. W: Korting HC, Sterry W 
(Hrsg) Therapeutische Verfahren in der Dermatologie. 2001, Blackwell 
Wissenschaft Berlin, 273-294. 
www.intechopen.com
Pharmacotherapy
Edited by Dr. Farid Badria
ISBN 978-953-51-0532-9
Hard cover, 194 pages
Publisher InTech
Published online 29, June, 2012
Published in print edition June, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The intent of this book is to provide an overview of current conceptualizations of Pharmacotherapy. The book
focuses on three major areas; diagnosis, treatment, and prevention for a wide array of diseases; Cognitive and
Psychological disorders (Schizophrenia and Nicotine addiction), Inflammatory disorders (New Chemical anti-
inflammatory and Immunotherapy), updated antihypertensive therapy and healing of ulcers with venous origin.
A separate chapter is dedicated to the rationality of drug use in earthquake injuries. The last chapter deals with
Imaging of potential therapeutic or diagnostic agents in animal models in the early stage of research. We hope
this book is useful to a wide range of people, from students first learning about Pharmacotherapy, to advanced
clinicians and researchers.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Z. Rybak, G Krasowski, R. Wajda and P. Ciesielczyk (2012). LavTIME - A Brand-New Treatment Method of
Lasting Wounds - A Multi-Centre Randomized Double-Blind Study on Effectiveness of Polyhexanide and
Betaine in Ulcers' Healing with Venous Origin, Pharmacotherapy, Dr. Farid Badria (Ed.), ISBN: 978-953-51-
0532-9, InTech, Available from: http://www.intechopen.com/books/pharmacotherapy/lavtime-a-brand-new-
treatment-method-of-lasting-wounds-a-multi-centre-randomized-double-blind-st
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
